Open-Label Trial of Cinnarizine in Migraine Prophylaxis

Authors

  • Mansooreh Togha MD,

  • Hossein Ashrafian MD,

  • Parvin Tajik MD


  • From the Department of Neurology, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran (Drs. Togha and Ashrafian); and Department of Epidemiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran (Dr. Tajik).

Address all correspondence to Dr. Mansooreh Togha, No. 94, 16th Floor, 2nd building, Satarkhan Complex, Satarkhan Street, Tehran, 14437-33653 Iran.

Abstract

Objective.—To assess the effectiveness and safety of cinnarizine as a migraine-preventive therapy.

Methods.—Sixty patients with more than 2 migraine headache attacks during a 4-week baseline entered the study and received a 25-mg tablet cinnarizine twice daily for the first 3 days and then 3 times daily. They were assessed on weeks 2, 6, 10, and 14. Reduction from baseline in 4-week migraine headache rate was the primary efficacy variable. Reduction in migraine attacks duration and severity was also evaluated.

Results.—The mean reduction in 4-week migraine headache rate was 4.6 ± 2.2 from the baseline of 6.2 ± 2.2 after 14 weeks of treatment, which was statistically significant (P < 0.001). Percent reduction in 4-week migraine frequency was 35% after 2 weeks, 74% after 6 weeks, 74% after 10 weeks, and 75% after 14 weeks of treatment. Significant reduction in attack duration (P < 0.001) and severity (P < 0.001) was also noted. No serious adverse events were observed in this series of patient.

Conclusion.—Cinnarizine is an efficacious and well-tolerated prophylactic antimigraine medication, which has early onset effectiveness.

Ancillary